Carregant...
Combining mTOR Inhibitors and T Cell-Based Immunotherapies in Cancer Treatment
SIMPLE SUMMARY: Several clinical protocols are exploring the anticancer effect of immunotherapy combined to targeted therapy. Indeed, emerging evidence demonstrates that small-molecule targeted inhibitors promote the antitumor immune response. In the case of mechanistic target of rapamycin (mTOR) in...
Guardat en:
| Publicat a: | Cancers (Basel) |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8002586/ https://ncbi.nlm.nih.gov/pubmed/33802831 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13061359 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|